tiprankstipranks
Advertisement
Advertisement

NMRA Stock Latest News

Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis
RatingsNeumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis
7d ago
NMRA
Neumora Maintained at Buy as NMRA-215 Advances Toward Phase 1; $5 Price Target Reaffirmed
PremiumRatings
Neumora Maintained at Buy as NMRA-215 Advances Toward Phase 1; $5 Price Target Reaffirmed
7d ago
NMRA
Neumora advances NMRA-215 with positive toxicology results
PremiumCompany Announcements
Neumora advances NMRA-215 with positive toxicology results
7d ago
8K
NMRA
Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study
PremiumThe Fly
Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study
7d ago
NMRA
Neumora Therapeutics price target lowered to $5 from $7 at RBC Capital
PremiumThe Fly
Neumora Therapeutics price target lowered to $5 from $7 at RBC Capital
21d ago
NMRA
Neumora Therapeutics price target lowered to $4 from $6 at Mizuho
PremiumThe FlyNeumora Therapeutics price target lowered to $4 from $6 at Mizuho
2M ago
NMRA
Neumora Therapeutics price target lowered to $5 from $8 at Needham
Premium
The Fly
Neumora Therapeutics price target lowered to $5 from $8 at Needham
2M ago
NMRA
Neumora Therapeutics price target lowered to $7 from $18 at H.C. Wainwright
Premium
The Fly
Neumora Therapeutics price target lowered to $7 from $18 at H.C. Wainwright
2M ago
NMRA
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
PremiumThe Fly
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
2M ago
LBRX
NMRA
Neumora Ends Navacaprant After Phase 3 Trial Failure
PremiumCompany Announcements
Neumora Ends Navacaprant After Phase 3 Trial Failure
2M ago
8K
NMRA
Neumora Therapeutics announces KOASTAL studies miss primary endpoint
PremiumThe Fly
Neumora Therapeutics announces KOASTAL studies miss primary endpoint
2M ago
NMRA
Neumora Shareholders Approve Directors, Auditor and Executive Pay
PremiumCompany Announcements
Neumora Shareholders Approve Directors, Auditor and Executive Pay
2M ago
8K
NMRA
Analyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts
PremiumRatingsAnalyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts
2M ago
NMRA
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst
Premium
Company Announcements
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst
2M ago
NMRA
Neumora Therapeutics Securities Lawsuit Enters New Procedural Phase as Plaintiffs Prepare New Complaint
Premium
Class Action
Neumora Therapeutics Securities Lawsuit Enters New Procedural Phase as Plaintiffs Prepare New Complaint
3M ago
NMRA
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
PremiumRatings
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
3M ago
NMRA
Analyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
PremiumRatings
Analyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
3M ago
NMRA
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
PremiumThe Fly
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
3M ago
NMRA
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
PremiumRatings
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
4M ago
NMRA
Neumora Therapeutics management to meet with Piper Sandler
PremiumThe FlyNeumora Therapeutics management to meet with Piper Sandler
4M ago
NMRA
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead
Premium
Company Announcements
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead
4M ago
NMRA
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access
Premium
Company Announcements
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access
4M ago
NMRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >